Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

February 1, 2024

https://www.globenewswire.com/news-release/2024/02/01/2821963/0/en/Clearmind-Medicine-Announces-Exclusive-Long-Term-Licensing-Agreement-with-Leading-Israeli-Research-Center.html

The licensing agreement refers to the company’s dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving

Tel Aviv, Israel / Vancouver, Canada, Feb. 01, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the signing of an exclusive long-term license agreement with BIRAD, a research & development company of Bar-Ilan University, to use the joint patent it has with BIRAD for innovative cocaine treatment.

Read more at globenewswire.com

Related news for (CMND)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.